Amarin sues U.S. FDA on free speech grounds over off-label speech

May 7, 2015 8:59 PM

17 0

May 7 (Reuters) - Amarin Corp Plc filed suit against the U.S. Food and Drug Administration on Thursday for restricting its right to promote its fish oil drug Vascepa for an unapproved, or off-label, use.

The suit, filed on Thursday in U.S. District Court for the Southern District of New York, argues that the FDA's ban violates Amarin's right to free speech under the First Amendment of the U.S. Constitution.

Also read: Court stay halts some work on Mountain Valley Pipeline

Read more

To category page